Puma Biotechnology (PBYI) Competitors $3.22 +0.04 (+1.26%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$3.22 -0.01 (-0.16%) As of 08/5/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. ADMA, CTMX, TRDA, RLAY, BCAX, ORGO, SEPN, ABUS, EOLS, and ZVRAShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Relay Therapeutics (RLAY), Bicara Therapeutics (BCAX), Organogenesis (ORGO), Septerna (SEPN), Arbutus Biopharma (ABUS), Evolus (EOLS), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Its Competitors ADMA Biologics CytomX Therapeutics Entrada Therapeutics Relay Therapeutics Bicara Therapeutics Organogenesis Septerna Arbutus Biopharma Evolus Zevra Therapeutics ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Which has higher earnings and valuation, ADMA or PBYI? ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M10.61$197.67M$0.8522.31Puma Biotechnology$230.50M0.69$30.28M$0.774.18 Do institutionals & insiders hold more shares of ADMA or PBYI? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 23.3% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer ADMA or PBYI? ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 45.92%. Puma Biotechnology has a consensus target price of $7.00, suggesting a potential upside of 117.39%. Given Puma Biotechnology's higher probable upside, analysts clearly believe Puma Biotechnology is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ADMA or PBYI more profitable? ADMA Biologics has a net margin of 45.01% compared to Puma Biotechnology's net margin of 16.37%. Puma Biotechnology's return on equity of 49.35% beat ADMA Biologics' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics45.01% 47.16% 30.51% Puma Biotechnology 16.37%49.35%18.25% Does the media refer more to ADMA or PBYI? In the previous week, ADMA Biologics had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 8 mentions for ADMA Biologics and 3 mentions for Puma Biotechnology. ADMA Biologics' average media sentiment score of 0.73 beat Puma Biotechnology's score of -0.21 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ADMA or PBYI? ADMA Biologics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. SummaryADMA Biologics beats Puma Biotechnology on 13 of the 17 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.83M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E Ratio4.1817.5328.9123.88Price / Sales0.69313.17445.5998.82Price / Cash3.7342.6035.6858.35Price / Book1.717.828.165.60Net Income$30.28M-$54.52M$3.25B$265.26M7 Day Performance1.90%2.86%1.17%-0.14%1 Month Performance-9.30%17.29%8.27%6.08%1 Year Performance-20.10%13.27%29.19%24.22% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.8658 of 5 stars$3.22+1.3%$7.00+117.4%-10.3%$157.83M$230.50M4.18200Upcoming EarningsADMAADMA Biologics4.2211 of 5 stars$18.00-0.1%$27.67+53.7%+67.8%$4.30B$426.45M21.18530Upcoming EarningsCTMXCytomX Therapeutics4.0105 of 5 stars$2.39-0.4%$5.33+123.2%+88.1%$193.49M$138.10M4.98170Upcoming EarningsTRDAEntrada Therapeutics3.2403 of 5 stars$6.23-4.7%$25.67+312.0%-59.7%$248.21M$210.78M8.07110Positive NewsUpcoming EarningsRLAYRelay Therapeutics1.9739 of 5 stars$3.70-1.1%$17.67+377.5%-50.3%$641.20M$10.01M-1.66330Upcoming EarningsBCAXBicara TherapeuticsN/A$11.81+0.5%$31.86+169.8%N/A$640.80MN/A0.0032News CoveragePositive NewsUpcoming EarningsORGOOrganogenesis4.344 of 5 stars$5.02-0.2%$6.50+29.5%+82.7%$638.07M$482.04M0.00950Upcoming EarningsSEPNSepterna1.3794 of 5 stars$13.83-0.4%$26.75+93.4%N/A$618.47M$1.08M0.00N/AABUSArbutus Biopharma2.1922 of 5 stars$3.35+4.0%$5.50+64.2%-5.8%$616.72M$6.17M-8.1790Positive NewsUpcoming EarningsEOLSEvolus3.6805 of 5 stars$9.28-2.6%$23.75+155.9%-33.1%$614.45M$266.27M0.00170News CoverageZVRAZevra Therapeutics2.0937 of 5 stars$10.81-3.7%$23.71+119.4%+45.2%$614.05M$23.61M0.0020Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies ADMA Biologics Competitors CytomX Therapeutics Competitors Entrada Therapeutics Competitors Relay Therapeutics Competitors Bicara Therapeutics Competitors Organogenesis Competitors Septerna Competitors Arbutus Biopharma Competitors Evolus Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
